arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

PAVmed Inc.

PAVM

$4.74 ▼ -0.04 (-0.84%) at close

12 Visible periods

24 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Neutral

auto_awesome

Analytical Summary

PAVmed Inc. shows mixed fundamentals. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $3.2M

Dividend Yield —

Revenue Growth -97.6% ↘

Op. Margin —

ROIC -64.2% ↘

FCF / Share $-7.81 ↘

Trailing P/E —

Price / Book 0.1x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

12-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$71.00K

↓ -97.6% —

Net Income Profit after all expenses

$401.00K

↓ -99.0% —

FCF / Share Free cash flow per share

$-7.81

↓ -124.8% —

Health Breakdown

Returns

Cash Quality

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗
Revenue Growth YoY (%)	-97.6% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-1320%)	20.0% Excellent ↓ Excellent Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+150%)	563.1% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+6939%)	-24.6% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-408%)	—	—	—	—	—	—	—	—
EPS Growth YoY (%)	N/M	N/M	-816.0% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	-53.8% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—	—	—	—
Net Income Growth YoY (%)	-99.0% Weak ↓ Weak Declining Year-over-year change in net income	N/M	27.9% Excellent ↑ Excellent Improving Year-over-year change in net income	-76.7% Weak ↓ Weak Declining Year-over-year change in net income	-46.9% Weak ↑ Weak Improving Year-over-year change in net income	-108.3% Weak ↓ Weak Declining Year-over-year change in net income	8.4% Fair ↑ Fair Improving Year-over-year change in net income	-88.8% Weak ↑ Weak Improving Year-over-year change in net income	-68.5% Weak Weak Year-over-year change in net income	-218.1% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	-124.8% Weak ↑ Weak Improving Year-over-year change in free cash flow	51.9% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	-787.9% Weak Weak Year-over-year change in free cash flow	-50.1% Weak Weak Year-over-year change in free cash flow	—	—	—	—	—	—	—	—
Revenue CAGR 3Y (%)	-42.7% Weak Weak Compound annual revenue growth over 3 years	81.7% Excellent Excellent Compound annual revenue growth over 3 years	—	—	—	—	—	—	—	—	—	—

💰 Are margins durable? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗
Effective Tax Rate (%) (%)	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—	—	—	—	—	—	—	—	—	—
FCF / Net Income (x)	-13.06x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	-0.84x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.81x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.82x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.84x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.64x Weak → Weak Stable Free cash flow relative to reported net income Optimal: > 1x	0.81x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.49x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	0.69x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—	—	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗
Return on Invested Capital (%)	-64.2% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	1408.6% Excellent ↑ Excellent Improving Return earned on debt + equity capital invested Optimal: > 10%	101.0% Excellent ↑ Excellent Improving Return earned on debt + equity capital invested Optimal: > 10%	742.0% Excellent ↑ Excellent Improving Return earned on debt + equity capital invested Optimal: > 10%	-69.7% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-973.0% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	295.3% Excellent ↓ Excellent Declining Return earned on debt + equity capital invested Optimal: > 10%	360.5% Excellent ↓ Excellent Declining Return earned on debt + equity capital invested Optimal: > 10%	222.8% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	1399.1% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—	—
Return on Capital (%) (%)	-56.2% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-145.1% Weak → Weak Stable Operating profit relative to total assets Optimal: > 10%	-207.7% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-168.4% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-62.5% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-118.1% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-197.4% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-124.3% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-490.0% Weak Weak Operating profit relative to total assets Optimal: > 10%	-649.2% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—
Return on Common Equity (%) (%)	1.2% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-92%)	—	119.2% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+695%)	—	-81.6% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-644%)	—	—	—	—	—	-280.3% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1968%)	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗
Interest Coverage (x)	—	-988.60x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-116.80x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-71.48x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	—	-440.58x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-437.61x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-4.42x Weak Weak Operating income divided by interest expense Optimal: > 5x	-11.09x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—	—
Net Debt (USD)	$-1.54M	$-1.19M	$-19.64M	$-39.74M	$-77.26M	$-17.26M	$-6.22M	$-8.22M	$-1.54M	$-585.68K	$-767.27K	$-839.08K

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗
Revenue per Share (USD)	$0.11	$0.31	$0.35	$0.00	$0.01	—	—	—	—	—	—	—
Basic EPS, GAAP (USD)	$-5.63	$3.30	$-9.16	$-1.00	$-0.65	—	—	—	—	—	—	—
Free Cash Flow per Share (USD)	$-7.81	$-3.47	$-7.23	$-0.81	$-0.54	—	—	—	—	—	—	—
Book Value per Share (USD)	$36.60	$-0.22	$-6.28	$-0.10	$0.71	$0.03	$-0.09	$-0.09	$-0.20	$-0.02	$0.05	—
Tangible Book Value per Share (USD)	$36.60	$-0.22	$-6.44	$-0.14	$0.69	$0.03	$-0.09	$-0.09	$-0.20	$-0.02	$0.05	—
Basic Weighted Avg Shares (shares)	670,466	9.67M	7.23M	89.08M	77.52M	—	—	—	—	—	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗
Working Capital (USD)	$-12.28M	$-33.28M	$-29.68M	$2.73M	$75.08M	—	$-5.33M	$-2.51M	$-920.28K	$-448.32K	$195.86K	—
Total Equity (USD)	$33.97M	$-2.50M	$-53.83M	$-9.68M	$61.67M	$1.90M	$-3.82M	$-2.31M	$-2.85M	$-319.07K	$633.92K	$794.83K

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗
Sales/Revenue/Turnover (USD)	$71.00K	$3.00M	$2.50M	$377.00K	$500.00K	—	—	—	—	—	—	—
Depreciation Expense (USD)	$105.00K	$1.20M	$2.93M	$2.46M	$226.00K	$23.00K	$14.23K	$9.79K	$7.11K	$3.79K	—	—
Net Income, GAAP (USD)	$401.00K	$39.79M	$-64.17M	$-88.98M	$-50.35M	$-34.28M	$-16.46M	$-17.97M	$-9.52M	$-5.65M	$-1.78M	—
Operating Cash Flow (USD)	$-5.21M	$-33.55M	$-52.04M	$-70.98M	$-40.59M	$-21.91M	$-13.36M	$-8.79M	$-6.61M	—	—	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 12 years · 45 quarters

PAVmed Inc.

Analytical Summary

12-Year Financial Trajectory

Health Breakdown

Statement lens

Benchmark Lens

Percentile Rankings

Peer Comparison

Compare PAVM with peers